BEIJING, July 8, 2024 /PRNewswire/ -- CASI Pharmaceuticals (Formerly Known As EntreMed, Inc.), Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products today announces appointment of Daniel Lang, MD as Chief Financial Officer and Senior Vice President, effective July 8th, 2024..

北京，2024年7月8日/PRNewswire/--CASI Pharmaceuticals（原名EntreMed，Inc。）Inc.（纳斯达克：CASI），一家开曼群岛注册的生物制药公司，专注于开发和商业化创新疗法和药品，今天宣布任命医学博士Daniel Lang为首席财务官和高级副总裁，自2024年7月8日起生效。。

Dr. Lang has more than 30 years of experience as a physician scientist, investor, and biotech executive. He is a cardiologist by training from UCSF, followed by 20 years of investment experience as a portfolio manager at Farallon Capital and Chief Investment Officer at RS Investments Value Group. Most recently, he was the President of Athenex cell therapy division and led clinical development of the NKT cell platform..

朗博士拥有30多年的医生、科学家、投资者和生物技术高管经验。他在加州大学旧金山分校接受培训，是一名心脏病专家，之后在Farallon Capital担任投资组合经理，并在RS Investments Value Group担任首席投资官，拥有20年的投资经验。最近，他是Athenex细胞治疗部门的总裁，并领导了NKT细胞平台的临床开发。。

'We are delighted to have Dan join us at this exciting time at CASI. His unique combination of clinical, operational and capital market experience will contribute to the strategic pivot of anti-CD38 program to focus on antibody mediated rejection (AMR) and Idiopathic thrombocytopenia purpura (ITP),' said Dr.

“我们很高兴丹能在这个激动人心的时刻加入我们。他将临床、运营和资本市场经验的独特结合，将有助于抗CD38计划的战略重点，专注于抗体介导的排斥反应（AMR）和特发性血小板减少性紫癜（ITP）。

Wei-Wu He, Chairman and CEO of CASI Pharmaceuticals..

CASI制药董事长兼首席执行官何伟（Wei Wu He）。。

Dr. Lang commented 'I am excited to join CASI to execute on the Company's strategy in maximizing the value of its pipeline products, especially CID-103 which has a great potential to address unmet medical needs for autoimmune disease patients.'

朗博士评论道：“我很高兴加入CASI，执行公司的战略，最大限度地提高其管道产品的价值，特别是CID-103，它有很大的潜力来解决自身免疫性疾病患者未满足的医疗需求。”

About CASI Pharmaceuticals

关于卡西制药

CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need.

卡西制药有限公司是一家生物制药公司，专注于在中国、美国和全世界开发和商业化创新疗法和药品。该公司专注于收购、开发和商业化产品，以增强其血液肿瘤治疗重点以及其他未满足医疗需求的领域。

The Company intends to execute its plan to become a leader by launching medicines in the Greater China market, leveraging the Company's China-based regulatory and commercial competencies and its global drug development expertise. The Company's operations in China are conducted through its wholly owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd., located in Beijing, China. .

该公司打算通过在大中华区市场推出药物，利用该公司在中国的监管和商业能力及其全球药物开发专业知识，实施其成为领导者的计划。该公司在中国的运营是通过其位于中国北京的全资子公司卡西制药（中国）有限公司进行的。。

Forward-Looking Statements

前瞻性声明

This announcement contains forward-looking statements. These statements are made under the 'safe harbor' provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as 'will,' 'expects,' 'anticipates,' 'future,' 'intends,' 'plans,' 'believes,' 'estimates,' 'confident' and similar statements.

本公告包含前瞻性声明。这些声明是根据1995年《美国私人证券诉讼改革法案》的“安全港”条款做出的。这些前瞻性陈述可以通过“意愿”、“预期”、“预期”、“未来”、“打算”、“计划”、“相信”、“估计”、“自信”等术语来识别。

Among other things, the business outlook and quotations from management in this announcement, as well as the Company's strategic and operational plans, contain forward-looking statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the 'SEC'), in in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties.

除其他外，本公告中的业务前景和管理层的报价，以及公司的战略和运营计划，都包含前瞻性陈述。公司还可以在向美国证券交易委员会（“SEC”）提交的定期报告、向股东提交的年度报告、新闻稿和其他书面材料以及高管、董事或员工向第三方的口头陈述中，做出书面或口头的前瞻性陈述。

Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the possibility that we may be delisted from trading on The Nasdaq Capital Market if we fail to satisfy applicable continued listing standards; the volatility in the market price of our ordinary shares; the risk of substantial dilution of existing shareholders in future share issuances; the difficulty of executing our business strategy on a global basis including China; our inability.

非历史事实的陈述，包括关于公司信念和期望的陈述，都是前瞻性陈述。前瞻性陈述涉及固有风险和不确定性。许多因素可能导致实际结果与任何前瞻性声明中包含的结果存在重大差异，包括但不限于以下因素：由于我们无法筹集足够的资金满足运营需求，我们可能无法持续经营的风险；如果我们未能满足适用的继续上市标准，我们可能会在纳斯达克资本市场上被摘牌；我们普通股市场价格的波动性；未来股票发行中现有股东被大幅稀释的风险；在包括中国在内的全球范围内执行我们的业务战略的困难；我们的无能。

COMPANY CONTACT:

公司联系人：

Rui Zhang

张睿（Rui Zhang）

CASI Pharmaceuticals, Inc.

卡西制药股份有限公司。

240.864.2643

240.864.2643

ir@casipharmaceuticals.com

ir@casipharmaceuticals.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/casi-pharmaceuticals-announces-appointment-of-daniel-lang-md-as-cfo-and-svp-302190346.html

查看原始内容以下载多媒体：https://www.prnewswire.com/news-releases/casi-pharmaceuticals-announces-appointment-of-daniel-lang-md-as-cfo-and-svp-302190346.html

SOURCE CASI Pharmaceuticals

来源CASI Pharmaceuticals

Company Codes: NASDAQ-SMALL:CASI

公司代码：NASDAQ-SMALL：CASI